Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a report published on Wednesday morning. The brokerage issued an overweight rating and a $25.00 price objective on the stock.

Several other research analysts have also commented on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. JMP Securities initiated coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. Maxim Group lifted their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Roth Mkm increased their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Finally, Canaccord Genuity Group decreased their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Zevra Therapeutics presently has a consensus rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $8.53 on Wednesday. The stock has a market capitalization of $455.30 million, a P/E ratio of -4.33 and a beta of 2.01. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The company has a 50 day moving average price of $8.78 and a 200 day moving average price of $7.58.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter in the prior year, the business earned ($0.40) earnings per share. Equities research analysts forecast that Zevra Therapeutics will post -1.96 EPS for the current year.

Institutional Trading of Zevra Therapeutics

Large investors have recently made changes to their positions in the company. FMR LLC boosted its stake in shares of Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after buying an additional 2,312,384 shares during the period. Stonepine Capital Management LLC purchased a new position in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $4,858,000. Vestal Point Capital LP acquired a new position in shares of Zevra Therapeutics in the third quarter valued at approximately $3,644,000. Propel Bio Management LLC purchased a new stake in shares of Zevra Therapeutics during the third quarter worth approximately $1,248,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Zevra Therapeutics by 14.2% during the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after purchasing an additional 129,600 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.